Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The 10 Most Persuasive Forerunners in Innovation - 2Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- 3Little Urban areas to Visit in Western Europe
- 4Insane Realities That Will Make You Reconsider How you might interpret History
- 5NASA unveils close-up pictures of the comet popping by from another star
- Seoul says sorry after unapproved drone flights into North Korea
- Eight Muslim nations condemn Israel's 'dangerous' new death penalty law
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Signature Scents: A Manual for Outstanding Fragrances
- Public Parks in the USA
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- Middle East hotels hit pandemic-era lows amid Iran war
- The Universe of Impeccable Pearls: A Manual for Valuable Gems
- The Red Sea strategy: What does Israel stand to gain from recognizing Somaliland?
